For patients with metastatic or surgically unresectable leiomyosarcoma, combination therapy with doxorubicin and trabectedin is associated with improved overall and progression-free survival compared ...

A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates. Neoadjuvant chemotherapy in high-risk soft ...

First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary ...

Clinical Trials for Leiomyosarcoma New clinical trials come up depending on what cancer researchers are working on. Some of the current ones for leiomyosarcoma are for a type of treatment called ...

An oral combination treatment may prevent the progression of advanced leiomyosarcoma, one of the most common subtypes of soft tissue sarcoma, according to a recent study published in The Lancet ...

Leiomyosarcoma (LMS) is a type of soft tissue sarcoma — and a very rare type of cancer. Doctors often find LMS cancer in the uterus. But it can occur in any of your body’s smooth muscles. This cancer ...

Doxorubicin alone has long been standard first-line therapy for advanced leiomyosarcoma, but doxorubicin plus trabectedin followed by trabectedin maintenance may improve outcomes. New research ...

Please provide your email address to receive an email when new articles are posted on . In a video interview, Sandra D’Angelo, MD, talked about a study of cabozantinib and temozolomide in patients ...

Cancer Trials Ireland and the Beatrice Pembroke Walsh Foundation join forces to improve access and research for sarcoma ...

Soft tissue sarcomas are a group of rare cancers that can occur in almost any part of the body and develop in tissues like muscle, fat, and nerves. The most common types are leiomyosarcoma, ...